MersV1, PubMed, Corpus, bibRecord, 001712

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

Identifieur interne : 001712 ( PubMed/Corpus ); précédent : 001711; suivant : 001713

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

Auteurs : Naru Zhang ; Rudragouda Channappanavar ; Cuiqing Ma ; Lili Wang ; Jian Tang ; Tania Garron ; Xinrong Tao ; Sumaiya Tasneem ; Lu Lu ; Chien-Te K. Tseng ; Yusen Zhou ; Stanley Perlman ; Shibo Jiang ; Lanying Du

Source :

Cellular & molecular immunology [ 2042-0226 ] ; 2016.

RBID : pubmed:25640653

English descriptors

KwdEn :
- Adjuvants, Immunologic (chemistry), Adjuvants, Immunologic (pharmacology), Animals, Antibodies, Viral (immunology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Female, Humans, Immunoglobulin G (immunology), Mice, Mice, Inbred BALB C, Middle East Respiratory Syndrome Coronavirus (immunology), Spike Glycoprotein, Coronavirus (immunology), Spike Glycoprotein, Coronavirus (pharmacology), Vaccines, Subunit (immunology), Vaccines, Subunit (pharmacology), Viral Vaccines (immunology), Viral Vaccines (pharmacokinetics).
MESH :
- chemical , chemistry : Adjuvants, Immunologic.
- chemical , immunology : Antibodies, Viral, Immunoglobulin G, Spike Glycoprotein, Coronavirus, Vaccines, Subunit, Viral Vaccines.
- chemical , pharmacokinetics : Viral Vaccines.
- chemical , pharmacology : Adjuvants, Immunologic, Spike Glycoprotein, Coronavirus, Vaccines, Subunit.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- Animals, Female, Humans, Mice, Mice, Inbred BALB C.

Abstract

Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines.

DOI: 10.1038/cmi.2015.03
PubMed: 25640653

Links to Exploration step

pubmed:25640653

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Zhang, Naru" sort="Zhang, Naru" uniqKey="Zhang N" first="Naru" last="Zhang">Naru Zhang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<affiliation><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, IA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ma, Cuiqing" sort="Ma, Cuiqing" uniqKey="Ma C" first="Cuiqing" last="Ma">Cuiqing Ma</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Lili" sort="Wang, Lili" uniqKey="Wang L" first="Lili" last="Wang">Lili Wang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tang, Jian" sort="Tang, Jian" uniqKey="Tang J" first="Jian" last="Tang">Jian Tang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tao, Xinrong" sort="Tao, Xinrong" uniqKey="Tao X" first="Xinrong" last="Tao">Xinrong Tao</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tasneem, Sumaiya" sort="Tasneem, Sumaiya" uniqKey="Tasneem S" first="Sumaiya" last="Tasneem">Sumaiya Tasneem</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<affiliation><nlm:affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai, Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation><nlm:affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<affiliation><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, IA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:25640653</idno>
<idno type="pmid">25640653</idno>
<idno type="doi">10.1038/cmi.2015.03</idno>
<idno type="wicri:Area/PubMed/Corpus">001712</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001712</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.</title>
<author><name sortKey="Zhang, Naru" sort="Zhang, Naru" uniqKey="Zhang N" first="Naru" last="Zhang">Naru Zhang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<affiliation><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, IA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ma, Cuiqing" sort="Ma, Cuiqing" uniqKey="Ma C" first="Cuiqing" last="Ma">Cuiqing Ma</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Wang, Lili" sort="Wang, Lili" uniqKey="Wang L" first="Lili" last="Wang">Lili Wang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tang, Jian" sort="Tang, Jian" uniqKey="Tang J" first="Jian" last="Tang">Jian Tang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tao, Xinrong" sort="Tao, Xinrong" uniqKey="Tao X" first="Xinrong" last="Tao">Xinrong Tao</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tasneem, Sumaiya" sort="Tasneem, Sumaiya" uniqKey="Tasneem S" first="Sumaiya" last="Tasneem">Sumaiya Tasneem</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name>
<affiliation><nlm:affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai, Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Tseng, Chien Te K" sort="Tseng, Chien Te K" uniqKey="Tseng C" first="Chien-Te K" last="Tseng">Chien-Te K. Tseng</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation><nlm:affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<affiliation><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, IA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Cellular & molecular immunology</title>
<idno type="eISSN">2042-0226</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (chemistry)</term>
<term>Adjuvants, Immunologic (pharmacology)</term>
<term>Animals</term>
<term>Antibodies, Viral (immunology)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Female</term>
<term>Humans</term>
<term>Immunoglobulin G (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus (pharmacology)</term>
<term>Vaccines, Subunit (immunology)</term>
<term>Vaccines, Subunit (pharmacology)</term>
<term>Viral Vaccines (immunology)</term>
<term>Viral Vaccines (pharmacokinetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Subunit</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Subunit</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25640653</PMID>
<DateCompleted><Year>2016</Year>
<Month>12</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2042-0226</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>2</Issue>
<PubDate><Year>2016</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Cellular & molecular immunology</Title>
<ISOAbbreviation>Cell. Mol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>180-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/cmi.2015.03</ELocationID>
<Abstract><AbstractText>Middle East respiratory syndrome (MERS), an emerging infectious disease caused by MERS coronavirus (MERS-CoV), has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike (S) protein receptor-binding domain (RBD) is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG (S377-588-Fc). Specifically, we compared several commercially available adjuvants, including Freund's adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fc to induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Naru</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Channappanavar</LastName>
<ForeName>Rudragouda</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, Iowa City, IA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Cuiqing</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Lili</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tang</LastName>
<ForeName>Jian</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Xiang-Ya Medical College, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Garron</LastName>
<ForeName>Tania</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tao</LastName>
<ForeName>Xinrong</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tasneem</LastName>
<ForeName>Sumaiya</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai, Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tseng</LastName>
<ForeName>Chien-Te K</ForeName>
<Initials>CT</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Yusen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Xiang-Ya Medical College, Central South University, Changsha, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perlman</LastName>
<ForeName>Stanley</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, Iowa City, IA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai, Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Lanying</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P01AI06099</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI109094</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI091322</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21AI109094</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P01 AI060699</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 AI060549</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>02</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Cell Mol Immunol</MedlineTA>
<NlmUniqueID>101242872</NlmUniqueID>
<ISSNLinking>1672-7681</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>09</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>01</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>01</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId>
<ArticleId IdType="pii">cmi201503</ArticleId>
<ArticleId IdType="doi">10.1038/cmi.2015.03</ArticleId>
<ArticleId IdType="pmc">PMC4786625</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2012 Jun 19;30(29):4341-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22682289</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jun;88(12):7045-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24719424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Immunol. 2010 Mar;31(3):103-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20153253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Saudi Pharm J. 2011 Oct;19(4):197-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23960760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Nov;19(11):1819-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24206838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19237568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2014 Jul;16(7):529-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24931059</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Immunol. 2012 Jun;32(3):595-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22318394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2008 Jan 15;180(2):948-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18178835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Cell Biol. 2004 Oct;82(5):488-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15479434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Life Sci. 2008 Oct;65(20):3231-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18668203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(1):e53568</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23320093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2009 Oct 10;393(1):144-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19683779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2013 Jun;7(3):129-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23836036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Nov 19;31(48):5745-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24091311</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Apr 15;203(8):1165-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21451004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(12):e81587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Oct 21;32(46):6170-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25240756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mucosal Immunol. 2014 May;7(3):589-601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24129165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Oct;19(10):1697-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24050621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2003 Apr;2(2):197-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12899571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2014 Jul;21(7):989-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24828092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Biol Ther. 2010 Apr;10(4):639-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20218923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Epidemiol. 2001;17(2):135-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11599686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2010 Jun;22(3):411-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20466528</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Nov 15;183(10):6186-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19864596</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2014 Jan 28;174:51-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24269505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18650390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19416838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2006 May 15;176(10):6085-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16670317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs Today (Barc). 2008 Jan;44(1):63-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18301805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol Sin. 2012 Jun;27(3):145-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22684468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(5):e37019</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22615877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(5):e63344</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23675482</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Sep;87(17):9953-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23824802</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2013 Jul;12(7):747-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23885820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2014 Jun;13(6):761-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24766432</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Feb;85(4):1896-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21123389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jun 19;26(26):3209-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18462843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2013;13:435</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24041010</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3099-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20133740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(11):e80559</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24260419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2009;154(7):1129-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19557497</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Apr 12;25(15):2832-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17092615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014;5(4):e01450-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25053787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Deliv. 2011 Aug;2(8):1057-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22826868</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biologicals. 2010 Sep;38(5):594-601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20659806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Prev Med Hyg. 2009 Jun;50(2):121-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20099444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Retrovirology. 2007;4:33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17509143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2010 Nov;17(11):1817-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20810680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Mar;86(5):2856-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22205743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(1):e16555</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21304591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2008 Oct 15;112(8):3303-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18660382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2007 Jun 15;316(5831):1628-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17569868</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12516-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25114257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2009 Apr;9(4):287-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19247370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2011 Aug;18(8):1358-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21715575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2013 Jul-Aug;15(8-9):625-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23791956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2013;18(24). pii: 20502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23787161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Immunol Immunopathol. 1998 Feb 27;61(2-4):291-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9613442</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014;5(3):e01146-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24781747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Jun 7;28(25):4123-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20433807</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001712 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001712 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:25640653
   |texte=   Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:25640653" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki